文献速递艾滋病与性传播感染结核与非结核分枝杆菌

接受含每日高剂量利福喷丁结核治疗患者的依非韦伦药代动力学与1型人类免疫缺陷病毒(HIV-1)病毒抑制

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
PubMed 文献 · Clin Infect Dis · 2022-01-01

在3期随机对照试验背景下,评估含每日高剂量利福喷丁(1200 mg)的结核方案对已病毒抑制且使用依非韦伦(EFV1)或新启动依非韦伦(EFV2)的HIV合并结核患者依非韦伦药代动力学和病毒抑制的影响。EFV1组70例、EFV2组41例可评估,合用结核药时依非韦伦表观口服清除率几何均值比分别为0.79(90%CI 0.72-0.85)和0.84(90%CI 0.69-0.97),多数患者达到目标谷浓度,支持无需调整剂量合用依非韦伦。

要点

  • 含每日高剂量利福喷丁(1200 mg)的结核方案轻度降低而非增加依非韦伦清除率。
  • EFV1组合用结核药时依非韦伦CL/F几何均值比为0.79(90%CI 0.72-0.85)。
  • EFV2组该比值为0.84(90%CI 0.69-0.97),支持无需调整依非韦伦剂量。

核心结论

  • 含每日高剂量利福喷丁的结核治疗轻度降低而非增加依非韦伦清除率,且达到治疗目标,支持在这些方案中合用依非韦伦而无需调整剂量。

研究设计与样本

  • 在3期随机对照试验背景下,已病毒抑制且使用含依非韦伦抗逆转录病毒治疗(EFV1)或新启动依非韦伦(EFV2)的HIV阳性个体接受含利福喷丁(1200 mg)、异烟肼、吡嗪酰胺及乙胺丁醇或莫西沙星的结核治疗。
  • EFV1组70例、EFV2组41例可评估参与者。

主要发现

  • EFV1组合用与未合用结核药时依非韦伦CL/F几何均值比为0.79(90%CI 0.72-0.85)。
  • EFV2组该几何均值比为0.84(90%CI 0.69-0.97)。
  • EFV1组第0、4、8、17周间期依非韦伦浓度>1 mg/L的参与者比例分别为96%、96%、88%、89%。
  • EFV2组在依非韦伦启动后约4周和8周时该比例为98%。

关键数值与推荐

  • 目标间期依非韦伦浓度>1 mg/L。
  • 若>80%参与者间期依非韦伦浓度达到该目标,则认为合用可接受。

临床怎么用

  • 作者结论支持在这些含每日高剂量利福喷丁的结核方案中合用依非韦伦而无需调整剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 4-month regimen containing rifapentine and moxifloxacin has noninferior efficacy compared to the standard 6-month regimen for drug-sensitive tuberculosis. We evaluated the effect of regimens containing daily, high-dose rifapentine on efavirenz pharmacokinetics and viral suppression in patients with human immunodeficiency virus (HIV)-associated tuberculosis (TB). METHODS: In the context of a Phase 3 randomized controlled trial, HIV-positive individuals already virally suppressed on efavirenz--containing antiretroviral therapy (ART) (EFV1), or newly initiating efavirenz (EFV2) received TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin. Mid-interval efavirenz concentrations were measured (a) during ART and TB cotreatment (Weeks 4, 8, 12, and 17, different by EFV group) and (b) when ART was taken alone (pre- or post-TB treatment, Weeks 0 and 22). Apparent oral clearance (CL/F) was estimated and compared. Target mid-interval efavirenz concentrations were > 1 mg/L. Co-treatment was considered acceptable if > 80% of participants had mid-interval efavirenz concentrations meeting this target. RESULTS: EFV1 and EFV2 included 70 and 41 evaluable participants, respectively. The geometric mean ratio comparing efavirenz CL/F with vs without TB drugs was 0.79 (90% confidence interval [CI] .72-.85) in EFV1 and 0.84 [90% CI .69-.97] in EFV2. The percent of participants with mid-interval efavirenz concentrations > 1mg/L in EFV1 at Weeks 0, 4, 8, and 17 was 96%, 96%, 88%, and 89%, respectively. In EFV2, at approximately 4 and 8 weeks post efavirenz initiation, the value was 98%. CONCLUSIONS: TB treatment containing high-dose daily rifapentine modestly decreased (rather than increased) efavirenz clearance and therapeutic targets were met supporting the use of efavirenz with these regimens, without dose adjustment. CLINICAL TRIALS REGISTRATION: NCT02410772.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Podany AT, Pham M, Sizemore E, et al. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022. PMID: 34918028. doi:10.1093/cid/ciab1037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。